T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLB Ltd
SLB
|
+$2.48B |
| 2 |
Kenvue
KVUE
|
+$1.5B |
| 3 |
Halliburton
HAL
|
+$1.12B |
| 4 |
Boeing
BA
|
+$950M |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$920M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.64B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.66B |
| 4 |
Johnson & Johnson
JNJ
|
+$1.56B |
| 5 |
Amazon
AMZN
|
+$1.17B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.76% |
| 2 | Healthcare | 16.83% |
| 3 | Financials | 10.91% |
| 4 | Consumer Discretionary | 10.77% |
| 5 | Communication Services | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
BorgWarner
BWA
$13.8B
| $13.9M | ﹤0.01% |
343,217
-44,176
| -11% | -$1.87M |
|
|
EFOR
1002
Everforth Inc
EFOR
$1.37B
| $13.9M | ﹤0.01% |
169,577
+17,286
| +11% | +$1.38M |
|
1003
Pentair
PNR
$10.7B
| $13.9M | ﹤0.01% |
213,921
+461
| +0.2% | +$31K |
|
1004
Doximity
DOCS
$4.74B
| $13.8M | ﹤0.01% |
651,514
-1,459,680
| -69% | -$39.8M |
|
|
CPRX
1005
DELISTED
Catalyst Pharmaceutical
CPRX
| $13.8M | ﹤0.01% |
1,178,168
+76,778
| +7% | +$1.03M |
|
1006
C.H. Robinson
CHRW
$17.5B
| $13.7M | ﹤0.01% |
159,558
+365
| +0.2% | +$34.1K |
|
1007
RB Global
RBA
$16B
| $13.7M | ﹤0.01% |
219,212
+19,115
| +10% | +$1.18M |
|
1008
Crown Holdings
CCK
$12.9B
| $13.6M | ﹤0.01% |
153,141
+2,250
| +1% | +$202K |
|
1009
AES
AES
$10.5B
| $13.5M | ﹤0.01% |
888,556
-6,363
| -0.7% | -$121K |
|
1010
Healthpeak Properties
DOC
$14.3B
| $13.4M | ﹤0.01% |
732,300
+2,145
| +0.3% | +$44K |
|
1011
KBR
KBR
$4.81B
| $13.3M | ﹤0.01% |
224,853
+1,338
| +0.6% | +$82.5K |
|
1012
Kinross Gold
KGC
$31.9B
| $13.2M | ﹤0.01% |
2,896,252
+612,031
| +27% | +$3M |
|
1013
Supernus Pharmaceuticals
SUPN
$2.74B
| $13.2M | ﹤0.01% |
477,380
-35,624
| -7% | -$1.08M |
|
1014
Apogee Therapeutics
APGE
$10.2B
| $13.1M | ﹤0.01% |
+615,950
| New | +$13.6M |
|
|
PYCR
1015
DELISTED
Paycor HCM, Inc. Common Stock
PYCR
| $12.9M | ﹤0.01% |
565,617
-4,078
| -0.7% | -$97.2K |
|
1016
Fortune Brands Innovations
FBIN
$5.78B
| $12.9M | ﹤0.01% |
207,452
-1,771,197
| -90% | -$122M |
|
1017
Ambev
ABEV
$43.8B
| $12.9M | ﹤0.01% |
4,995,520
| – | – |
|
1018
Celldex Therapeutics
CLDX
$3.35B
| $12.9M | ﹤0.01% |
468,055
-10,519
| -2% | -$330K |
|
1019
Brookfield Renewable
BEP
$10.6B
| $12.8M | ﹤0.01% |
588,368
+7,512
| +1% | +$202K |
|
1020
LCI Industries
LCII
$2.6B
| $12.8M | ﹤0.01% |
108,882
-433
| -0.4% | -$54.2K |
|
1021
RXO
RXO
$3.85B
| $12.6M | ﹤0.01% |
637,069
-31,058
| -5% | -$612K |
|
1022
Pacira BioSciences
PCRX
$924M
| $12.5M | ﹤0.01% |
408,989
+1,447
| +0.4% | +$52.2K |
|
1023
Centrus Energy
LEU
$3.83B
| $12.5M | ﹤0.01% |
219,893
+40,094
| +22% | +$1.73M |
|
|
JNPR
1024
DELISTED
Juniper Networks
JNPR
| $12.4M | ﹤0.01% |
444,865
+1,171
| +0.3% | +$33.7K |
|
1025
Petrobras
PBR
$115B
| $12.4M | ﹤0.01% |
824,377
| – | – |
|
Similar funds
T. Rowe Price Associates's Q3 2023 Portfolio in Review
As of Q3 2023, T. Rowe Price Associates held 2,959 positions worth $682B, down 4.9% from $718B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Trading was light in Q3 2023: portfolio turnover was 4.7%. T. Rowe Price Associates opened 69 new positions and exited 71, leaving the 2,959-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 32% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q3 2023 buy was Maplebear: 6,435,942 shares worth $191M.
- T. Rowe Price Associates added most to SLB Ltd in Q3 2023, an estimated $2.48B increase.
- T. Rowe Price Associates's biggest Q3 2023 reduction was Microsoft, cutting an estimated $2.64B.
- T. Rowe Price Associates fully exited Life Storage, Inc. in Q3 2023, selling an estimated $285M.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $682B portfolio in Q3 2023.
- T. Rowe Price Associates opened 69 new positions and closed 71 in Q3 2023.
- T. Rowe Price Associates's portfolio value fell 4.9% quarter-over-quarter to $682B.
Based on T. Rowe Price Associates's 13F filing for Q3 2023, filed 14 Nov 2023.